Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
作者:David J. Augeri、Jeffrey A. Robl、David A. Betebenner、David R. Magnin、Ashish Khanna、James G. Robertson、Aiying Wang、Ligaya M. Simpkins、Prakash Taunk、Qi Huang、Song-Ping Han、Benoni Abboa-Offei、Michael Cap、Li Xin、Li Tao、Effie Tozzo、Gustav E. Welzel、Donald M. Egan、Jovita Marcinkeviciene、Shu Y. Chang、Scott A. Biller、Mark S. Kirby、Rex A. Parker、Lawrence G. Hamann
DOI:10.1021/jm050261p
日期:2005.7.1
Efforts to further elucidate structure-activity relationships (SAR) within our previously disclosed series of beta-quaternary amino acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the beta-position of alpha-cycloalkyl-substituted glycines. Despite poor systemic exposure, vinyl-substituted compounds showed extended
为了进一步阐明我们先前公开的一系列β-季氨基酸连接的1-cis-4,5-methanoprolinenitrile二肽基肽酶IV(DPP-IV)抑制剂的结构-活性关系(SAR),人们进行了研究α-环烷基取代的甘氨酸的β位。尽管全身暴露不良,但乙烯基取代的化合物在急性大鼠离体血浆DPP-IV抑制模型中显示出更长的作用持续时间。制备了氧化的推定代谢物,并在测量Zucker(fa / fa)大鼠葡萄糖清除率的功效模型中显示了其前体的效价和延长的作用时间。这种方法扩展到金刚烷基甘氨酸衍生的抑制剂导致发现了高效抑制剂,